

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1477)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 25, 2022

The Board announces that all the resolutions as set out in the Notice were duly passed by the Shareholders as ordinary resolutions by way of poll at the Extraordinary General Meeting.

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”) is pleased to announce the poll results of the extraordinary general meeting of the Company (the “**Extraordinary General Meeting**”) held at 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai, the PRC at 3:00 p.m. on Friday, November 25, 2022.

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Extraordinary General Meeting and notice of the Extraordinary General Meeting (the “**Notice**”) dated November 4, 2022. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Extraordinary General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To approve and confirm the refreshment of the Scheme Mandate Limit to 53,424,000 Shares, being approximately 7.95% of the total Shares in issue as of the date of approval by the Independent Shareholders rounded down to nearest whole board lot of 500 Shares (assuming there is no other change in the number of total Shares in issue since the Latest Practicable Date and up to the date of approval by the Independent Shareholders), and to grant the Board an advanced mandate to allot and issue up to 51,031,000 Award Shares within the Scheme Mandate Limit for the purpose of satisfying all options, awards and other incentives to be granted under all share schemes of the Company in accordance with the articles of association of the Company, provided that the allotment and issue of 51,031,000 Award Shares shall be in addition to, and shall not prejudice or revoke any existing or such other general or specific mandates which may from time to time be granted to the Directors prior to the passing of this resolution.	390,047,676 (84.624001%)	70,870,823 (15.375999%)
2.	To approve and confirm the set of the Service Provider Sublimit as 5,342,000 Shares, being 0.795% of the total Shares in issue as of the date of approval by the Independent Shareholders rounded down to nearest whole board lot of 500 Shares (assuming there is no other change in the number of total Shares in issue since the Latest Practicable Date and up to the date of approval by the Independent Shareholders).	390,047,676 (84.624001%)	70,870,823 (15.375999%)
3.	Subject to all applicable laws, rules, regulations, the applicable grant letter and conditional upon the passing of resolution 1 above, to approve and confirm the conditional grant of Awards representing 4,320,000 Award Shares to Mr. Liu and Awards representing 137,000 Award Shares to Dr. Hu in accordance with the terms of the 2021 Share Award Scheme and the transactions contemplated thereunder.	390,344,676 (84.688438%)	70,573,823 (15.311562%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
4.	Subject to and conditional upon the passing of resolution 1 above, to authorize anyone or more of the Directors (except for any Director who has an interest in the transactions contemplated) (i) to exercise the powers of the Company to allot and issue the ordinary Shares within the Scheme Mandate Limit, such that the Shares shall rank <i>pari passu</i> in all respects among themselves and with the existing ordinary Shares in issue at the date of the allotment and issue of the Shares; and (ii) to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in resolutions 1, 2 and 3 above.	390,344,676 (84.688438%)	70,573,823 (15.311562%)

Please refer to the Notice for the full text of the resolutions proposed at the Extraordinary General Meeting.

As more than 50% of the votes were cast in favor of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Extraordinary General Meeting.

The total number of issued Shares as of the date of the Extraordinary General Meeting was 672,287,745 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all resolutions. Mr. Liu, being the Connected Grantee under the Proposed Connected Grant, holding a total of 18,420,230 Shares, which represents approximately 2.74% of the issued share capital of the Company as of the date of the Extraordinary General Meeting, was required to and did abstain from voting on all of the above ordinary resolutions. Dr. Hu, being the Connected Grantee under the Proposed Connected Grant, holding a total of 3,374,335 Shares, which represents approximately 0.50% of the issued share capital of the Company as of the date of the Extraordinary General Meeting, was required to and did abstain from voting on all of the above ordinary resolutions.

Save as aforesaid, there were (a) no Shares entitling the holders to attend and abstain from voting in favor at the Extraordinary General Meeting as set out in Rule 13.40 of the Listing Rules, (b) no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Extraordinary General Meeting, and (c) no Shareholders being required under the Listing Rules to abstain from voting on the resolutions proposed at the Extraordinary General Meeting and no Shareholders stating his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Extraordinary General Meeting.

The executive directors of the Company, Mr. Ye LIU and Dr. Zhaopeng HU, the non-executive directors of the Company, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG and the independent non-executive directors of the Company, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG attended the Extraordinary General Meeting, either in person or by means of telecommunication.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Extraordinary General Meeting.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, November 25, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.